Social Sciences · Education
Macroencapsulation\nDevice with Anti-inflammatory Membrane\nModification Enhances Long-Term Viability and Function of Transplanted\nβ Cells
MinJi Park (13990092), Hyun Lee (468713), Yerim Jang (20420301), Min Ji Kim (501406), Younghak Cho (261162), Sophie S. Liu (8105741), JungEun Lee (17386525), Surim Shim (20420304), Hyun-Do Jung (6432527), Hyejeong Seong (1561135), Kisuk Yang (1759669)
See on the mapAbstract
Treating\ntype 1 diabetes (T1D) through β-cell macroencapsulation\nis a promising long-term solution, but it faces challenges such as\nimmune-mediated fibrosis on the capsule surface, which impairs cell\nfunctionality and compromises longevity and effectiveness. This study\npresents an approach for including an anti-inflammatory molecule on\nthe macroencapsulation device (MED) using initiated chemical vapor\ndeposition for the surface modification of poly(tetrafluoroethylene)\n(PTFE) membranes. The surface-modified MEDs significantly reduced\nfibrosis, improved β-cell viability and functionality, and promoted\nM2 macrophage polarization, which is associated with anti-inflammatory\neffects. This MED displayed improved glycemic control in a streptozotocin-induced\ndiabetic mouse model for 45 days. The findings underscore the potential\nof surface-modified MEDs for improving T1D management by mitigating\ninflammation and enhancing the therapeutic efficacy of β-cell\nencapsulation.